For over 100 years, Menarini has been investing in different research areas, from heart and respiratory diseases to infectious diseases, and, as part of its mission, the Group has always strived to focus on innovative research in the oncology area that could have a positive impact on all lives touched by cancer.

As World Cancer Day on February 4th approaches, the Menarini Group reaffirms its ongoing commitment to the fight against cancer with the goal to make a difference in patients’ lives every day.

These goals of excellence are made possible by a vision aiming to create and build innovative solutions that will cater to the patients’ individual needs. This is why the Group is focusing on precision medicine, a healthcare approach that takes into account differences in patients’ genetic profiles, environments and lifestyles.

In 2020, Menarini took another step in this direction and further cemented its goals through the acquisition o Stemline Therapeutics, a U.S. based biopharmaceutical company focused on the development of novel oncology therapeutics. The acquisition of Stemline represented a turning point for Menarini’s oncology research, allowing the company to enter into an area of unmet medical need.

Since the acquisition of the company, Menarini and Stemline teams have been working tirelessly to focus on new research approaches in different oncology areas, such as solid tumors and hematological diseases.

The Group is highly committed in solid tumors research like Breast Cancer, which is the most frequent malignancy among women that has been seeing a rising global incidence in the last decades. As this trend is likely to continue, finding new approaches and solutions that can address the unexplored medical needs of patients with breast cancer is an increasingly pressing matter.
Furthermore, the company is also investigating Colorectal Cancers, a leading cause of cancer-related death worldwide, and Glioblastoma, the most frequent and aggressive brain tumor which remains, as of today, still incurable.

When it comes to hematologic malignancies, the Menarini Group is heavily involved in the fight against BPDCN, a rare blood cancer with historical poor outcomes; as well as against other malignancies such as Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma and Multiple Myeloma.

Menarini is a company built on the foundations of dedication, commitment, collaboration, vision and ambition. Throughout the years, Menarini employees and researchers have contributed towards establishing a legacy that has become a symbol of excellence worldwide. This is especially true when it comes to Menarini’s commitment in the fight against cancer, which reflects the company’s innate caring nature and, above all, its core values that always put the patient first and strive to transform lives touched by cancer.